Hopp til innhold
NHI.no
Annonse

Svettekjertelbetennelse (hidradenitis suppurativa): Forebygging

Innhold i artikkelen

Røykestopp er svært viktig fordi røyking fører til nedsatt blodsirkulasjon i de ytre hudlag, og kroppens evne til å reparere skader svekkes betydelig. Dersom man er overvektig, kan vektreduskjon lindre plagene. 

Annonse

Skadet hud disponerer ofte for forverring - man bør stelle fint med huden. Klærne bør være luftige og ledige for å unngå stramming over sårene. Daglig bruk av deodorant kan hindre at huden blir oppbløtt, men bør ikke brukes dersom huden blir irritert. Man bør unngå hårfjerning og barbering, fordi det kan medføre små skader i huden. Det bør ikke trykkes/klemmes på nye knuter. 

Daglig varsom vask kan redusere lukt og hindre infeksjon. En mild såpe med nøytral pH kan brukes. Eventuelt kan man bruke klorheksidin i perioder. 

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Hidradenitis suppurativa . Referanselisten for dette dokumentet vises nedenfor

  1. Helsedirektoratet (2021). Nasjonal faglig retningslinje for antibiotika i primærhelsetjenesten nettdokument. Oslo: Helsedirektoratet (sist faglig oppdatert 16. november 2021, lest jan 2022).
  2. Collier F, Smith RC, Morton CA. Diagnosis and management of hidradenitis suppurativa. British Medical Journal 2013; 346: f2121. doi:http://dx.doi.org/10.1136/bmj.f2121
  3. Ingram JR, Woo PN, Chua SL, Ormerod AD, Desai N, Kai AC, Hood K, Burton T, Kerdel F, Garner SE, Piguet V. Interventions for hidradenitis suppurativa. Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No.: CD010081. DOI: 10.1002/14651858.CD010081.pub2. The Cochrane Library
  4. Jfri A, Nassim D, O'Brien E, et al. Prevalence of Hidradenitis Suppurativa A Systematic Review and Meta-regression Analysis. JAMA Dermatol 2021. pmid:34037678 PubMed
  5. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009 Apr. 60(4):539-61.
  6. Kelly G et al. Vitamin D status in hidradenitis suppurativa. Br J Dermatol 2014 doi: 10.1111/bjd.12900 DOI
  7. Crowley JJ, Mekkes JR, Zouboulis CC, et al. Association of Hidradenitis Suppurativa Disease Severity with Increased Risk for Systemic Comorbidities. Br J Dermatol. 2014; 171: 1561-5. PMID: 24842009 PubMed
  8. Ulschmid C, Serrano L, Wu R et al. African American race is a risk factor for severe hidradenitis suppurativa. Int J Dermatol. 2022 Oct 2. Epub ahead of print. PMID: 36183313. PubMed
  9. Wipperman J, Bragg DA, Litzner B. Hidradenitis Suppurativa: Rapid Evidence Review. Am Fam Physician. 2019 Nov 1;100(9):562-569. PMID: 31674740.
  10. Ravi S, Miles JA, Steele C, et al. Patient Impressions and Outcomes After Clinic-Based Hidradenitis Suppurativa Surgery. JAMA Dermatol 2022. pmid:34985494 PubMed
  11. Ingram JR. Hidradenitis suppurativa: Management. UpToDate last updated Jan 13, 2022. UpToDate
  12. Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012 Jan 12. 366(2):158-64.
  13. Danielsen K, Tzellos T, Antonsen OH, Pritzier EC. Veileder for behandling av hidradenitis suppurativa i Norge. Norsk forening for dermatologi og venerologi. 2019. www.legeforeningen.no
  14. Kimball AB, Okun MM, Williams DA, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016; 375(5):422-34. doi: 10.1056/NEJMoa1504370.
  15. Bechara FG, Podda M, Prens EP, et al. Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa The SHARPS Randomized Clinical Trial. JAMA Surg 2021; 156: 1001-9. pmid:34406349 PubMed
  16. Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 2023. pmid:36746171 PubMed
  17. Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet 2024. pmid:38795716 PubMed
  18. Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: A practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol 2018. pmid:30176066 PubMed
  19. Soria A, Canoui-Poitrine F. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patient’s outcome assessment. Dermatology 2009; 218: 134-5. DOI:10.1159/000182261. DOI
  20. Boer J, Nazary M. Long term effects of acitretin therapy for hidradenitis suppurativa. Br J Dermatol 2011; 164: 170-5. DOI:10.1111/j.1365-2133.2010.10071.x DOI
  21. Nikolakis G, Kyrgidis A, Zouboulis CC. Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data. Am J Clin Dermatol. 2019 Aug;20(4):503-513. PMID: 31073704. PubMed
  22. Dhaliwal S, Nguyen M, Vaughn AR et al. Effects of Zinc Supplementation on Inflammatory Skin Diseases: A Systematic Review of the Clinical Evidence. Am J Clin Dermatol. 2020 Feb;21(1):21-39. PMID: 31745908.
  23. Brocard A, Knol AC. Hidradenitis suppurativa and zinc: a new therapeutic approach. Dermatology 2007; 214: 325-7. doi:10.1159/000100883 DOI
  24. Nordic Nutrition Recommendations 2012
  25. van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 2010; 63: 475. pmid:20708472 PubMed
  26. Madan V, Hindle E, Hussain W, August PJ. Outcomes of treatment of nine cases of recalcitrant severe hidradenitis suppurativa with carbon dioxide laser. Br J Dermatol. 2008 Dec. 159(6):1309-14.
  27. Egeberg A, Gislason GH, Hansen PR. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol 2016. doi: 10.1001/jamadermatol.2015.6264 DOI
Annonse
Annonse